Advisory Semantics: When Words Get In The Way Of Science At FDA Panels
Executive Summary
Industry experts offer advice on how sponsors can prevent advisory committee meetings from going awry due to confusing questions; some suggest eliminating votes actually may create clearer panel outcomes.
You may also be interested in...
Genzyme Will Appeal Lemtrada “Complete Response” After FDA Seeks More Trials
Rater-blinded design for multiple sclerosis claim netted an approval in Europe but a rejection by FDA, which was concerned about bias related to open label studies.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.